Immutep (NASDAQ:IMMP) Stock Price Down 4.6% – Here’s What Happened

Immutep Limited (NASDAQ:IMMP) shares were down 4.6% during mid-day trading on Monday . The stock traded as low as $2.00 and last traded at $2.08. 226,482 shares changed hands during trading, an increase of 5% from the average session volume of 214,748 shares. The stock had previously closed at $2.18.

Wall Street Analyst Weigh In

Separately, Robert W. Baird lifted their price objective on Immutep from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Friday, November 15th.

Immutep Price Performance

The company’s fifty day moving average price is $1.99 and its two-hundred day moving average price is $2.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.25 and a current ratio of 18.25.

Institutional Trading of Immutep

Several large investors have recently made changes to their positions in the business. XY Capital Ltd acquired a new position in Immutep during the 2nd quarter worth about $105,000. XTX Topco Ltd acquired a new stake in Immutep in the 2nd quarter valued at about $26,000. Finally, Meridian Wealth Management LLC raised its stake in shares of Immutep by 4.5% in the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock worth $881,000 after acquiring an additional 17,250 shares during the last quarter. Institutional investors own 2.32% of the company’s stock.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.